-
1 Comment
GenMark Diagnostics, Inc is currently in a long term uptrend where the price is trading 41.9% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.4.
GenMark Diagnostics, Inc's total revenue rose by 84.1% to $50M since the same quarter in the previous year.
Its net income has increased by 63.8% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 1.8% to $-10M since the same quarter in the previous year.
Based on the above factors, GenMark Diagnostics, Inc gets an overall score of 4/5.
Industry | |
---|---|
Exchange | F |
CurrencyCode | EUR |
ISIN | None |
Sector |
Market Cap | 1B |
---|---|
PE Ratio | None |
Target Price | None |
Beta | 3.06 |
Dividend Yield | 0.0% |
GenMark Diagnostics, Inc. designs and manufactures multiplex molecular diagnostic solutions to enhance patient care, improve quality metrics, and reduce the total cost-of-care for laboratory professionals, healthcare providers, and customers in the United States and internationally. It offers ePlex systems to streamline the diagnostic workflow from physician order entry to the release of the final report, automate and accelerate order entry and results reporting, notify practitioners that test results are available, enable operation on every shift, minimize system downtime and ensure patients and physicians have access to rapid test results, and reduce avoidable medical errors; ePlex software to support the needs of laboratory and healthcare systems, streamline tasks across the diagnostic process from order-to-report, improve productivity at every level, improve order-to-report turnaround time, reduce labor costs, and eliminate potential transcription errors with bi-directional LIS capabilities; XT-8 systems for processing multiple tests; ePlex panels that include respiratory pathogen and blood culture identification (BCID) Panels to identify the viral and bacterial organisms associated with upper respiratory infection, provide broad coverage of organisms that can lead to sepsis along with the resistance genes, and aid clinicians in the identification of bacterial and fungal organisms; and XT-8 panels to provide sensitive and specific respiratory virus detection with an optimized workflow to maximize laboratory efficiency. The company serves customers through distributors. GenMark Diagnostics, Inc. was formerly known as Osmetech plc and changed its name to GenMark Diagnostics, Inc. in June 2010. The company was incorporated in 2010 and is based in Carlsbad, California. As of April 21, 2021, GenMark Diagnostics, Inc. operates as a subsidiary of Roche Holding AG.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GNF.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025